Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma

被引:0
作者
Irina Proskorovsky
Philip Lewis
Cathy D Williams
Karin Jordan
Charalampia Kyriakou
Jack Ishak
Faith E Davies
机构
[1] Evidera,Centre for Clinical Haematology
[2] Celgene GmbH,Klinik und Poliklinik für Innere Medizin IV
[3] Nottingham University Hospital,Department of Haematology
[4] Universitätsklinikum Halle (Saale),undefined
[5] Northwick Park and Royal Free Hospitals,undefined
[6] Institute of Cancer Research and Royal Marsden Hospital,undefined
来源
Health and Quality of Life Outcomes | / 12卷
关键词
EORTC QLQ-C30; EORTC QLQ-MY20; EQ-5D; Health-related quality of life; Multiple myeloma; Oncology; Utility values;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 104 条
[1]  
Tosh JC(2011)Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals Value Health 14 102-109
[2]  
Longworth LJ(2012)Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome) Health Technol Assess 16 1-114
[3]  
George E(2009)Mapping the EORTC QLQ-C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data Value Health 12 167-171
[4]  
Brazier JE(1989)Generic and disease-specific measures in assessing health status and quality of life Med Care 27 S217-S232
[5]  
Rowen D(2012)Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial Eur J Haematol 89 16-27
[6]  
Mavranezouli I(2013)Lenalidomide, melphalan and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial Haematologica 98 784-788
[7]  
Tsuchiya A(2011)The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities Health Qual Life Outcomes 9 106-1203
[8]  
Young T(2012)Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients Qual Life Res 21 1193-1157
[9]  
Yang Y(2009)Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments Value Health 12 1151-434
[10]  
Barkham M(2010)Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences Eur J Health Econ 11 427-414